```html

Neonatal Respiratory Distress Syndrome (RDS)

Overview

Respiratory distress syndrome (RDS), also called hyaline membrane disease, is a condition that primarily affects premature infants whose lungs have not yet produced enough surfactant – a substance that keeps the tiny air‑sac structures (alveoli) open during breathing. Without adequate surfactant, the alveoli collapse, making it extremely difficult for the newborn to exchange oxygen and carbon dioxide.

• Who it affects: Infants born before 34 weeks of gestation are at highest risk, but RDS can also occur in late‑preterm babies (35‑36 weeks) and, rarely, in full‑term infants with genetic surfactant‑protein defects.
• Prevalence: In the United States, about 1‑2% of live births develop RDS, but the rate rises dramatically with decreasing gestational age—approximately 30% of infants born at 28 weeks and 70% of those born at 24 weeks develop the condition [1]. Worldwide, RDS remains a leading cause of neonatal mortality, accounting for an estimated 15–20% of deaths in infants < 28 days old [2].

Symptoms

Symptoms of neonatal RDS usually appear within minutes to a few hours after birth and may progress rapidly. The classic clinical picture includes:

• Tachypnea: Breathing rate > 60 breaths per minute.
• Retractions: Visible pulling of the chest wall (sternal, intercostal, or supraclavicular) as the baby works harder to breathe.
• Grunting: A harsh, forced exhalation sound that helps keep the airways open.
• Nasal flaring: Widening of the nostrils during inspiration.
• Chest wall “rocking” (see‑saw respirations): As the infant alternates between deep inhalations and shallow exhalations.
• Cyanosis: Bluish discoloration of the lips, tongue, or extremities due to low oxygen levels.
• Apnea episodes: Brief pauses in breathing (often < 20 seconds) that may be accompanied by bradycardia.
• Low oxygen saturation: Pulse oximetry < 90% despite supplemental oxygen.
• Hazy, ground‑glass appearance on chest X‑ray: While not a symptom, this radiographic sign often supports the clinical diagnosis.

Causes and Risk Factors

RDS is fundamentally a surfactant deficiency problem, but several maternal, fetal, and environmental factors influence its development.

Primary cause

• Immature type II pneumocytes: These cells produce surfactant; they mature around 34–35 weeks gestation.

Major risk factors

• Prematurity: The most powerful predictor—risk inversely proportional to gestational age.
• Maternal diabetes: Hyperglycemia leads to fetal hyperinsulinemia, which delays surfactant synthesis.
• Cesarean delivery without labor: Labor triggers catecholamine release that accelerates surfactant release.
• Second‑hand smoke exposure: Nicotine interferes with lung development.
• Maternal hypertension or pre‑eclampsia: Alters placental blood flow and fetal lung maturation.
• Multiple gestation (twins, triplets, etc.): Often results in earlier delivery.
• Genetic surfactant‑protein mutations: Rare, but can cause RDS in term infants.
• Perinatal asphyxia: Low oxygen during birth can worsen surfactant deficiency.

Diagnosis

RDS is a clinical diagnosis supported by imaging and laboratory tests. Prompt recognition is essential because the condition can deteriorate quickly.

Clinical assessment

• Physical exam focusing on respiratory rate, effort, and oxygenation.
• Continuous pulse‑oximetry to monitor SpO₂.

Imaging

• Chest X‑ray: Classic “ground‑glass” opacity with low lung volumes and air‑filled bronchial trees (hyaline membranes).

Laboratory tests

• Blood gas analysis: Shows low PaO₂ and often respiratory alkalosis due to hyperventilation.
• Surfactant level (research setting): Measured in tracheal aspirates, but not routinely performed.

Scoring systems

Some NICUs use the Downes’ score or the Silverman–Andersen Re‑Scoring system to quantify respiratory distress severity and guide treatment decisions.

Treatment Options

Management aims to provide enough oxygen, reduce the work of breathing, and replace or stimulate surfactant. Treatment is individualized based on gestational age, severity, and the infant’s overall condition.

Surfactant therapy

• Prophylactic surfactant: Given within 15 minutes of birth to infants < 30 weeks gestation or weighing < 1,250 g.
• Rescue surfactant: Administered when RDS is diagnosed after birth (typically < 2 hours).
• Common preparations: Beractant (Survanta®), Poractant alfa (Curosurf®), and Calfactant (Infasurf®).

Respiratory support

• Continuous Positive Airway Pressure (CPAP): First‑line for mild‑moderate RDS; maintains alveolar patency.
• Mechanical ventilation: Required for severe RDS or when CPAP fails. Gentle ventilation strategies (low tidal volume, permissive hypercapnia) reduce lung injury.
• High‑Frequency Oscillatory Ventilation (HFOV): Considered when conventional ventilation cannot maintain oxygenation.
• Extracorporeal Membrane Oxygenation (ECMO): Rare, reserved for refractory cases in specialized centers.

Pharmacologic adjuncts

• Caffeine citrate: Reduces apnea of prematurity and may improve ventilator weaning.
• Inhaled nitric oxide (iNO): Not routinely used for RDS alone but may help if pulmonary hypertension co‑exists.
• Antibiotics: Given empirically if infection cannot be ruled out.

Supportive care

• Thermoregulation – maintain neutral temperature to reduce metabolic demand.
• Fluid management – avoid both under‑ and over‑hydration; monitor electrolytes.
• Nutrition – early minimal enteral feeds (trophic feeding) to promote gut development.

Family‑centered care

Parental presence, skin‑to‑skin (kangaroo) care, and clear communication improve outcomes and reduce stress for families.

Living with Neonatal Respiratory Distress Syndrome

While RDS is an acute condition, many infants who survive experience a prolonged NICU stay and later follow‑up care. Below are practical tips for families.

• Follow‑up appointments: Ensure regular visits with neonatology, pulmonology, and developmental specialists.
• Vaccinations: Keep immunizations up to date, especially for RSV prophylaxis (palivizumab) in high‑risk infants.
• Monitor growth: Weight gain and head‑circumference are key indicators of overall health.
• Watch for respiratory infections: Promptly treat colds, coughs, or fever; seek care early.
• Home environment: Use humidifiers if the air is dry, keep the home smoke‑free, and avoid exposure to strong chemicals.
• Developmental stimulation: Engage in age‑appropriate play, tummy time, and talk to the baby to support neurodevelopment.
• Parental mental health: NICU stays are stressful; consider counseling, support groups, or hospital social‑work services.

Prevention

Because prematurity is the dominant risk factor, strategies that delay or prevent early birth are the most effective ways to reduce RDS incidence.

• Antenatal corticosteroids: Administer betamethasone or dexamethasone to mothers at risk of preterm delivery between 24‑34 weeks gestation; this accelerates fetal lung surfactant production and cuts RDS risk by 50%‑60% [3].
• Optimized maternal health: Control diabetes, hypertension, and avoid smoking or illicit drug use.
• Progesterone therapy: For women with a history of spontaneous preterm birth, weekly 17‑hydroxyprogesterone caproate can lower preterm delivery rates.
• Timely tocolysis: When preterm labor starts, short‑term use of medications (e.g., nifedipine) can buy time for steroid administration.
• Delivery planning: Whenever possible, allow labor to start naturally before a scheduled cesarean, as labor itself promotes surfactant release.
• Infection control: Treat maternal infections promptly (e.g., group B Streptococcus, urinary tract infections) to reduce preterm birth risk.

Complications

If RDS is not promptly and adequately treated, it can lead to short‑ and long‑term complications.

Acute complications

• Air‑leak syndromes – pneumothorax, pneumomediastinum, or pulmonary interstitial emphysema.
• Bronchopulmonary dysplasia (BPD) – chronic lung disease caused by prolonged ventilator or oxygen exposure.
• Intraventricular hemorrhage (IVH) – especially in very low birth weight infants.
• Sepsis – compromised lung barrier may facilitate bacterial translocation.
• Persistent pulmonary hypertension of the newborn (PPHN).

Long‑term sequelae

• Chronic respiratory issues – increased risk of asthma, recurrent wheeze, and reduced lung function into adulthood.
• Neurodevelopmental delays – BPD and prolonged hypoxia are linked with cognitive and motor impairments.
• Growth restriction – infants with severe RDS often experience slower weight gain.

When to Seek Emergency Care

---

References:

1. American Academy of Pediatrics. Neonatal Respiratory Distress Syndrome. 2023. https://www.aap.org.
2. World Health Organization. Neonatal mortality statistics. 2022. https://www.who.int.
3. Mayo Clinic. Surfactant therapy for premature infants. 2024. https://www.mayoclinic.org.
4. Cleveland Clinic. Bronchopulmonary Dysplasia in the NICU. 2023.
5. National Institutes of Health. Prematurity and Lung Development. 2024.

```